LATEST

AbbVie to profit from new Viekira Pak usesFDA expanded the use of ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets without ribavirin (Viekira Pak, AbbVie) this week to treat patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A).
Biosimilars pose problems for Medicare beneficiaries
Biosimilars pose problems for Medicare beneficiariesSurprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.
Drugmaker commits to “responsible” prices
This diabetes drug is safer for the heart: StudyThe generic metformin (Mallinkrodt) significantly reduced the risk of dying from heart attack and stroke compared to other common diabetes medications, according to a new study.
Why FDA pulled cholesterol drugs off marketFDA took the unusual step of withdrawing approval of two cholesterol-lowering drugs late last week.
Top 7 new facts about drug spendingAs organizations and politicians continue to sound the alarm that drug prices are rising, another new report confirmed the trend. Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous year, according to a new report from the IMS Institute for Healthcare Informatics.
FDA committee recommends approving rare liver disease drugFDA advisory committee recently voted to recommend approval of obeticholic acid (Ocaliva, Intercept Pharmaceuticals, Inc.) for the treatment of primary biliary cholangitis (PBC). If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.
New leukemia drug availableFDA recently approved venetoclax (Venclexta, AbbVie and Genentech) to treat chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least 1 prior therapy
Biosimilar approvals deemed “too slow”While FDA’s approval last week of infliximab-dyyb (Inflectra, Celltrion and Hospira), a biosimilar to Remicade (Janssen Biotech) for rheumatoid arthritis, Chron’s disease and other conditions is positive, FDA’s approval pace for biosimilars is too slow, according to a pharmacy benefit manager (PBM).
Diabetes drugs may be linked to heart failure, FDA warnsType 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA’s new Drug Safety Communication.

Poll

View Results